Saniona AB (publ) (SANION.ST)
SEK 8.05
(3.34%)
SEK 8.05
(3.34%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 16.84 Million SEK | 10.19% |
| 2022 | 15.28 Million SEK | 45.86% |
| 2021 | 10.47 Million SEK | 27.81% |
| 2020 | 8.19 Million SEK | 208.43% |
| 2019 | 2.65 Million SEK | -95.16% |
| 2018 | 54.88 Million SEK | 165.24% |
| 2017 | 20.69 Million SEK | -72.38% |
| 2016 | 74.92 Million SEK | 449.68% |
| 2015 | 13.63 Million SEK | -37.24% |
| 2014 | 21.71 Million SEK | 59.21% |
| 2013 | 13.64 Million SEK | 75.65% |
| 2012 | 7.76 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 6.03 Million SEK | 12.28% |
| 2024 Q2 | 8.01 Million SEK | 32.9% |
| 2023 Q3 | 5.45 Million SEK | 41.47% |
| 2023 Q2 | 3.85 Million SEK | 78.21% |
| 2023 Q4 | 5.37 Million SEK | -1.41% |
| 2023 FY | 16.84 Million SEK | 10.19% |
| 2023 Q1 | 2.16 Million SEK | -34.6% |
| 2022 Q2 | 2.96 Million SEK | -55.26% |
| 2022 FY | 15.28 Million SEK | 45.86% |
| 2022 Q1 | 6.62 Million SEK | 129.95% |
| 2022 Q4 | 3.3 Million SEK | 38.44% |
| 2022 Q3 | 2.38 Million SEK | -19.43% |
| 2021 FY | 10.47 Million SEK | 27.81% |
| 2021 Q1 | 3.43 Million SEK | -4.31% |
| 2021 Q4 | 2.88 Million SEK | 27.25% |
| 2021 Q3 | 2.26 Million SEK | 19.47% |
| 2021 Q2 | 1.89 Million SEK | -44.88% |
| 2020 FY | 8.19 Million SEK | 208.43% |
| 2020 Q4 | 3.59 Million SEK | 66.73% |
| 2020 Q1 | 459 Thousand SEK | -89.9% |
| 2020 Q2 | 1.99 Million SEK | 333.77% |
| 2020 Q3 | 2.15 Million SEK | 8.24% |
| 2019 Q2 | 687 Thousand SEK | -59.94% |
| 2019 Q4 | 4.54 Million SEK | 1674.61% |
| 2019 Q3 | 256 Thousand SEK | -62.74% |
| 2019 FY | 2.65 Million SEK | -95.16% |
| 2019 Q1 | 1.71 Million SEK | -22.61% |
| 2018 Q4 | 2.21 Million SEK | -95.03% |
| 2018 Q2 | 3.76 Million SEK | -13.16% |
| 2018 Q1 | 4.34 Million SEK | -6.06% |
| 2018 Q3 | 44.55 Million SEK | 1082.25% |
| 2018 FY | 54.88 Million SEK | 165.24% |
| 2017 Q2 | 4.34 Million SEK | -42.34% |
| 2017 Q4 | 4.62 Million SEK | 10.37% |
| 2017 Q1 | 7.53 Million SEK | 39.33% |
| 2017 Q3 | 4.18 Million SEK | -3.7% |
| 2017 FY | 20.69 Million SEK | -72.38% |
| 2016 Q2 | 3.04 Million SEK | -80.79% |
| 2016 Q1 | 15.85 Million SEK | 767.71% |
| 2016 FY | 74.92 Million SEK | 449.68% |
| 2016 Q4 | 5.41 Million SEK | -89.31% |
| 2016 Q3 | 50.61 Million SEK | 1561.56% |
| 2015 Q3 | 1.95 Million SEK | -60.9% |
| 2015 Q4 | 1.82 Million SEK | -6.55% |
| 2015 FY | 13.63 Million SEK | -37.24% |
| 2015 Q1 | 4.84 Million SEK | 30.32% |
| 2015 Q2 | 5 Million SEK | 3.14% |
| 2014 Q3 | 5.24 Million SEK | -10.69% |
| 2014 FY | 21.71 Million SEK | 59.21% |
| 2014 Q4 | 3.72 Million SEK | -29.1% |
| 2014 Q1 | 3.32 Million SEK | 0.0% |
| 2014 Q2 | 5.87 Million SEK | 76.64% |
| 2013 FY | 13.64 Million SEK | 75.65% |
| 2012 FY | 7.76 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 71.019% |
| Ziccum AB (publ) | 3.74 Million SEK | -349.426% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 97.266% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 66.644% |
| Mendus AB (publ) | 28.48 Million SEK | 40.885% |
| Genovis AB (publ.) | 158.23 Million SEK | 89.357% |
| Intervacc AB (publ) | 8.01 Million SEK | -110.106% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -285.002% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 90.12% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 61.637% |
| Aptahem AB (publ) | 2.63 Million SEK | -540.146% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -1527.053% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -21770.13% |
| Fluicell AB (publ) | 3.33 Million SEK | -404.494% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -2.639% |
| Biovica International AB (publ) | 7.29 Million SEK | -131.001% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -1299.834% |
| AcouSort AB (publ) | 10.55 Million SEK | -59.606% |
| Xintela AB (publ) | 78 Thousand SEK | -21489.744% |
| Abliva AB (publ) | 137 Thousand SEK | -12191.971% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 70.764% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -736.147% |
| OncoZenge AB (publ) | 3000.00 SEK | -561233.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -10764.516% |
| CombiGene AB (publ) | 5.54 Million SEK | -203.745% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 98.605% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.019% |
| Corline Biomedical AB | 25.03 Million SEK | 32.721% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -196.583% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -2235.645% |
| I-Tech AB | 120.86 Million SEK | 86.067% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 87.442% |
| Cyxone AB (publ) | 5.14 Million SEK | -227.117% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -138.865% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -57.904% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -49.955% |
| Nanologica AB (publ) | 1.44 Million SEK | -1067.013% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -31673.585% |
| BioInvent International AB (publ) | 71.46 Million SEK | 76.435% |
| Alzinova AB (publ) | 270 Thousand SEK | -6137.037% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 52.186% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1051.044% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -496.74% |
| Simris Alg AB (publ) | 4.35 Million SEK | -286.771% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -12853.846% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 92.946% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -73117.391% |